Compare AbCellera Biologics Inc (ABCL) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Caesars Entertainment Inc — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Caesars Entertainment Inc trades at $29.89 (market cap $6.18B). The key difference: Caesars Entertainment Inc is far larger — about 2.6× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | CZR | |
|---|---|---|
Market Cap | $2.35B | $6.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $31.51 |
52-Week Low | $2.78 | $18.14 |
Enterprise Value | $1.99B | $30.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CZR trades at $30.35, down 0.13% with a neutral technical stance despite bullish moving averages. The company reported a net loss of $502M in 2025 with negative margins, though revenue grew to $11.49B. Valuation ratios like P/E of 10.42 and P/S of 0.54 appear attractive, but recent earnings misses and a pending acquisition by Fertitta Entertainment at $31.00 per share dominate sentiment. Cash flow trends show improving operational performance with net cash flow narrowing to -$32M in 2025.
The outlook is mixed: the acquisition offers a near-term floor, but operational losses and high debt of $12.03B pose risks. Analysts are cautious with 63.3% hold ratings, citing competitive pressures and integration uncertainties. Investors should weigh the buyout premium against fundamental weaknesses in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
